# Enable Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enable-medicine

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.enablemedicine.com
- Total disclosed funding: $60M
- Latest round: Series A (Apr 6, 2022)
- Investors on record: 6

## About

Enable Medicine Inc. is a US-based company specializing in advanced AI and machine learning solutions for the discovery and development of targeted biological therapies, aimed to enhance biopharma research and drug development.Founded in 2019 and headquartered in Menlo Park, US, Enable Medicine Inc. focuses on creating innovative technologies for biotechnology and pharmaceutical firms. The company has successfully completed 3 deals, with its most recent funding round being a Series A of USD 60.00 mn raised from investors including Anthos Capital, Axial, Breyer Capital, General Catalyst Partners, Initialized Capital, and Presight Capital, leading to a total amount raised of USD 60.00 mn and a current valuation of USD 178.07 mn. Sunil Bodapati serves as the CEO, guiding the company through its strategic objectives.Enable Medicine specializes in providing solutions that utilize advanced artificial intelligence (AI) and machine learning (ML) to streamline the discovery and development of targeted biological therapies. Central to their operations is the Enable Medicine Platform, a cloud-based biodata infrastructure designed for the comprehensive analysis of multimodal biological data. This platform enables biopharma companies to thoroughly investigate complex datasets, facilitating the identification of novel therapeutic candidates and improving research outcomes. Their services cater primarily to biotechnology and pharmaceutical entities across key markets in North America, Europe, and Asia, where there is a growing demand for innovative therapeutic solutions.Enable Medicine generates revenue through strategic partnerships and subscriptions with biopharma clients leveraging their AI-driven platform. Their model is based on providing access to proprietary tools and methodologies vital for drug research and development. These partnerships predominantly involve annual or multi-year licensing agreements, allowing clients to utilize the platform for their research purposes. While specific pricing details are proprietary, the company's offerings are designed to meet the various needs of their clientele, reflecting the growing demand for AI and ML technologies in the pharmaceutical industry.In December 2024, Enable Medicine Inc. was acquired by General Inception, enhancing its capabilities within the drug development and biotech ecosystems. The company's future growth strategy includes the potential launch of new products designed to further streamline drug development processes. Additionally, Enable Medicine plans to expand its operations into emerging markets, targeting regions that exhibit increasing demand for biotech solutions. The recent Series A funding will support these initiatives, allowing the company to invest in innovation and market expansion efforts.

## Funding rounds

- Series A, Apr 6, 2022, $60M — General Catalyst Partners, Anthos Capital, Axial, Initialized Capital, Breyer Capital, Presight Capital

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A
- Anthos Capital (https://capitalatlas.ai/funds/anthos-capital) — Series A
- Axial — Series A
- Initialized Capital (https://capitalatlas.ai/funds/initialized-capital) — Series A
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series A
- Presight Capital — Series A